Update from Oxford-Harrington Rare Disease Centre
The Oxford‑Harrington Rare Disease Centre announced today that funding through the FA Alliance Innovation Fund had been awarded to five Oxford researchers to advance new therapeutic approaches for Friedreich’s ataxia.
FARA CEO Jennifer Farmer said, “The FA Alliance established by Oxford-Harrington, brings together basic, translational and clinical researchers, and a multi-disciplinary approach, which we believe is essential for translating discoveries to treatments. The new research projects announced today through the FA Alliance Innovation Fund give individuals and families living with FA hope and confidence in our mission to treat and cure FA. We are grateful for this partnership and commitment from the OHC and its philanthropic partner and look forward to supporting the research teams as they begin this important work.”
